Innovative Therapies | Transforming Lives


Partnering and Collaborations

Kineta is actively seeking strategic partnerships aimed at advancing our development pipeline. Beyond partnerships with industry, we also have a strong interest in establishing collaborative research agreements.  We actively collaborate with a broad array of private, government, biodefense and industry partners to advance our innovative research.

To further explore partnering and collaboration opportunities with Kineta, please email us or call 206-378-0400.

Neuroscience: Chronic Pain Program


Kineta is collaborating with Genentech, a member of the Roche Group, to develop our first in class α9/α10 nicotinic acetylcholine receptor (nAChr) antagonists for the treatment of chronic pain.  To learn more about our collaboration with Genentech please read the press release here.

Biodefense: LHF-535

Kineta received a Wellcome Trust Translation Fund Award of up to $7.2M to advance the development of a novel antiviral therapy to treat Lassa haemorrhagic fever.  The goal of the collaboration is to complete Phase 1a and Phase 1b safety studies in human subjects and position LHF-535 for Phase 2 evaluation in Lassa fever patients.  To learn more about our collaboration with The Wellcome Trust, please read the press release here.

Biodefense: Innate Immune Antivirals and Vaccine Adjuvant

Kineta is collaborating with the National Institutes of Health (NIH) to develop our broad spectrum antivirals and vaccine adjuvant programs.  These projects have been funded in whole or in party with Federal funds from the National Institute of Allergy and Infectious Diseases.  The funds from NIH are used to advance development of compounds that trigger the RIG-I pathway, activate IRF-3 and induce an antiviral response.  To learn more about our collaboration with NIH, please read the following press releases:  PR 1    PR 2     PR3